| NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | RECRUITING | PHASE1 | 2025-09 | 2032-10 | 2028-02 |
| NCT06500273 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING | PHASE2 | 2024-06-18 | 2031-08-24 | 2027-08-24 |
| NCT05714345 | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-03-31 | 2029-10 | 2024-02-20 |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | TERMINATED | PHASE1, PHASE2 | 2021-06-06 | 2023-10-11 | 2023-10-11 |
| NCT04696731 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-02-24 | 2025-12 | 2025-10 |
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-05-21 | 2029-05 | 2025-08 |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-09-23 | 2027-09 | 2027-09 |
| NCT03939026 | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-05-01 | 2026-08 | 2021-10-23 |